Afatinib Dimaleate

Early clinical activity observed across multiple ErbB-driven tumor types, including EGFR extracellular domain (ECD)-mutant cancers, for which no approved targeted therapies currently exist Brain penetration and preliminary clinical findings support continued development of EO1001 in biomarker-selected populations, including patients with CNS-involved disease Analysis of the complete safety, efficacy, pharmacokinetic and biomarker dataset underway ahead of planned presentation at a peer-reviewed medical meeting MENLO PARK, CA AND MELBOURNE, AU / ACCESS Newswire / July 30, 2026 / Edison Oncology Holding Corp. (“Edison Oncology” or the “Company”) and Senz Oncology Pty Ltd. (“Senz Oncology”) today announced the completion of enrollment in the ongoing Phase 1-2a study of EO1001, Edison Oncology’s oral, brain-penetrant pan-ErbB inhibitor, following the Phase 2 expansion cohorts (described as actively enrolling at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting). The trial (ANZCTR: ACTRN12620000583943), conducted in collaboration with Senz Oncology at Monash Health and The Alfred Hospital in Melbourne, Australia, is evaluating the safety, pharmacokinetics, and preliminary antitumor activity of EO1001 in patients with advanced ErbB-driven solid tumors, including those with CNS involvement. Fifty-two patients were screened and thirty-four enrolled across seven ascending dose cohorts (2.5-90 mg once daily orally) and an expansion cohort. EO1001 was generally well tolerated; the most frequent treatment-related adverse events observed to date were diarrhoea, rash, and fatigue (predominantly Grade 1-2 and consistent with known class effects of ErbB inhibitors), with dose-limiting toxicity (diarrhoea) observed at higher dose levels. A full analysis of the safety dataset across the complete enrolled population is underway. In preclinical models, EO1001 achieved brain-to-plasma exposure ratios exceeding 4:1 and tumor-tissue accumulation more than 20-fold higher than erlotinib in EGFR-positive intracranial xenograft mouse tumor models, supporting its potential to address CNS-involved disease. This differentiator was reflected in the trial’s inclusion of patients with brain metastases and primary CNS tumors such as glioblastoma. In an earlier interim analysis of the dose-escalation phase, 10 of 14 evaluable patients treated at doses of 50 mg once daily or higher achieved stable disease or partial response (three partial responses). Disease control and tumor shrinkage were observed across a range of ErbB-positive tumor types including gastric, ovarian, cervical, colorectal, bladder, and glioblastoma (GBM). The companies plan to present updated efficacy, pharmacokinetic, and biomarker data reflecting the full enrolled population at a peer-reviewed medical meeting in the second half of 2026. “Completing enrollment is a key milestone for the EO1001 program and for our biomarker-directed strategy more broadly,” said Jeffrey A. Bacha, chief executive officer of Edison Oncology. “ECD mutations remain one of the most under-recognized mechanisms of resistance and disease progression in ErbB-driven cancers, and the early activity we have seen in this trial – including in heavily pretreated patients with EGFR ECD-altered glioblastoma – reinforces why EO1001 was designed to address this biology. It’s fitting that our investigators chose to hold the final enrollment slot for a patient with this mutation profile; this additional patient will provide further insight into how EO1001 behaves in ECD-mutant disease, and we plan to build on those observations as we advance the program. With enrollment now complete, our focus turns to a full analysis of the safety, efficacy, and biomarker dataset, which we look forward to sharing at a future peer-reviewed medical meeting.” “Patients whose tumors harbor ErbB extracellular domain mutations, often across a wide range of cancer types, frequently have few remaining options by the time they reach a trial like this one,” said Dr. Sophia Frentzas, Monash Health, coordinating investigator for the study. “Preclinical data showing strong brain penetration for EO1001 was one of the reasons this trial was of real interest to us, given how few therapies reach CNS disease at meaningful concentrations. What’s been encouraging clinically is that the disease control, and in some cases meaningful tumor shrinkage, that we’ve observed in patients with CNS involvement, including recurrent GBM, is consistent with that preclinical profile. Completing enrollment allows us to build a more complete picture of how the drug is performing across dose levels and tumor types, which is exactly what a trial at this stage is designed to do.” As Edison Oncology has previously reported, EGFR extracellular domain (ECD) mutations drive tumor growth through a mechanism that is structurally distinct from the kinase-domain mutations targeted by all currently approved EGFR inhibitors, including osimertinib, erlotinib, afatinib, and dacomitinib – leaving patients with these alterations no approved targeted therapy option. EGFR ECD mutations occur across multiple tumor types representing large patient populations with high unmet need. In glioblastoma – the most common and lethal primary brain tumor, where EGFR alterations are found in approximately 40-50% of cases – ECD mutations including EGFRvIII and recurrent missense variants such as R108 and A289 substitutions collectively account for the majority of EGFR alterations, with ECD missense variants alone representing approximately 10-15% of all GBM cases. In colorectal cancer, acquired EGFR ECD mutations emerge as a clinically important resistance mechanism to anti-EGFR antibody therapy (cetuximab, panitumumab) in approximately 15-30% of patients who progress on these treatments. ECD-driven EGFR signaling has also been observed in subsets of neuroendocrine tumors and other solid tumor malignancies. Because EO1001 is designed as a pan-ErbB inhibitor, the same ECD-driven mechanism of resistance extends beyond EGFR to HER2 and HER4, potentially broadening the addressable opportunity: Non-small cell lung cancer (NSCLC) – HER2 mutations occur in ~2-4% of NSCLC overall; S310F/Y accounts for approximately 11-15% of HER2-mutant NSCLC cases, making it one of the most common non-kinase-domain HER2 alterations in this tumor type. Bladder/urothelial carcinoma, particularly the micropapillary variant – HER2 ECD mutations (primarily S310F/Y) have been reported in up to 40% of micropapillary urothelial carcinoma (MPUC) cases, compared with roughly 9% in non-micropapillary urothelial carcinoma; a larger follow-up cohort found ECD mutations in ~4% of all urothelial bladder cancer, nearly 30% of which were MPUC. Gastric/esophageal adenocarcinoma – ERBB2 mutations occur in approximately 7-8% of advanced gastric cancers, with S310F/Y accounting for roughly 19-20% of those mutations; HER2-amplified disease has shown early tumor shrinkage with EO1001 in this trial. Breast cancer, including HER2-nonamplified and invasive lobular subtypes – ERBB2 mutations are enriched in invasive lobular carcinoma (ILC), occurring in approximately 5.7% of ILC cases versus 1.4% in invasive ductal carcinoma; ILC accounts for 10-15% of all breast cancers. Prostate neuroendocrine carcinoma – HER2 mutations occur in greater than 10% of cases, among the highest prevalence reported for any tumor type. Cutaneous melanoma – ERBB4 mutations occur in approximately 19% of melanoma cases, with the majority of mutations concentrated in the receptor’s extracellular domain. In the current trial, multiple patients with recurrent glioblastoma harboring EGFR ECD alterations – including EGFRvIII and A289 variants – experienced prolonged stable disease, and additional tumor shrinkage was observed in HER2-amplified esophageal cancer and EGFR-driven head and neck cancer. Across these settings, available EGFR- and HER2-targeted therapies, designed to block the intracellular kinase domain, have demonstrated limited activity, leaving patients with few options – underscoring the case for a biomarker-selected, tumor-agnostic approach. EOHC-1001-01 is a two-stage, open-label, multi-centre Phase 1-2a study evaluating ascending single and multiple doses of EO1001 in adults with advanced or metastatic ErbB-positive solid tumors, including patients with CNS involvement, who have relapsed after or are unsuitable for approved therapies. The dose-escalation stage used an accelerated titration design transitioning to a standard 3+3 design upon the first Grade ≥2 treatment-related adverse event, followed by an expansion cohort of up to 20 patients at the recommended dose level. Primary objectives are safety and tolerability; secondary objectives include determination of a recommended Phase II dose, pharmacokinetic characterization, and preliminary antitumor activity by RECIST 1.1 and/or RANO criteria. EO1001 is an investigational, orally administered, brain-penetrating, irreversible pan-ErbB inhibitor designed to target wild-type and structurally altered EGFR, HER2, and HER4. In preclinical models, EO1001 achieved brain-to-plasma exposure ratios exceeding 4:1 and tumor-tissue accumulation more than 20-fold higher than erlotinib in EGFR-positive intracranial xenograft mouse tumor models, supporting its potential in CNS-involved disease. Edison Oncology holds exclusive worldwide rights to develop and commercialize EO1001 outside of China, Hong Kong, and Taiwan. With enrollment now complete, the Company is actively seeking development partnerships to advance EO1001 into biomarker-selected expansion and registration-directed studies across ErbB-driven tumor types, with a particular focus on the ECD mutation-defined patient population. Edison Oncology is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined cancers with significant unmet need. The Company’s approach centers on identifying compounds with established clinical safety profiles and demonstrated anticancer activity, then applying contemporary tools in genomics, biomarker science, and mechanistic biology to define the patient populations most likely to benefit – an approach made possible by advances in precision oncology that were not available when many of these compounds were first studied. The Company advances programs through a capital-efficient model combining internal development with strategic co-development and licensing partnerships, retaining meaningful rights while enabling rapid clinical advancement. Edison Oncology’s pipeline targets patient populations with no currently approved targeted therapy, including patients with EGFR extracellular domain mutations (EO1001), ARID1A-deficient cancers (EO3001), and CDA-high tumors (EO4426). To learn more, please visit https://www.edisononcology.com/ and follow us for updates on LinkedIn. Senz Oncology Pty Ltd, is a privately-held company based in Melbourne, Australia, is Edison Oncology’s Australian clinical development partner and the trial sponsor for the EOHC-1001-01 study, conducted at Monash Health and The Alfred Hospital. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified by words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” or by statements indicating that certain actions “may,” “could,” “should” or “might” occur. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Hayden IR Brett Maas(646) 536-7331brett@haydenir.com or James Carbonara(646)-755-7412james@haydenir.com View Full Article Here | Download PDF Edison Oncology and Senz Oncology Complete Enrollment in Phase 1–2a Trialof EO1001, Advancing Development in ErbB-Driven Cancers Edison Oncology Presents EO1001 Trials-in-Progress Poster at ASCO 2026, Highlighting Differentiated Activity in EGFR Extracellular Domain Mutant Cancers with No Approved Targeted Therapy

The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across various cancer indications. Additionally, the expected launch of therapies such as Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), and others will further propel the market growth. LAS VEGAS, June 15, 2026 /PRNewswire/ -- DelveInsight's EGFR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Head and neck cancer (HNC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging EGFR inhibitors, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan). Key Takeaways from the EGFR Inhibitors Market Report The market size for EGFR inhibitors was found to be USD 7 billion in the 7MM in 2025. The United States accounted for the largest EGFR inhibitor treatment market size, approximately 60% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report provides the total potential number of patients in the indications, such as Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), Head and neck cancer (HNC), and others. In 2025, the 7MM had approximately ~330,000 incident cases of EGFR Inhibitors. Leading EGFR inhibitor companies, such as Cullinan Oncology, Taiho Pharma, ArriVent BioPharma, Akeso Biopharma, Summit Therapeutics, Pfizer, Daiichi Sankyo, AstraZeneca, Merck, Kelun-Biotech, CSPC Pharmaceutical, Shanghai JMT-Bio, Bristol-Myers Squibb, AbbVie, Lantern Pharma, Wayshine Biopharm, Teligene US, Genprex, J Ints Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, DualityBio, ORIC Pharmaceuticals, BeOne Medicines (formerly BeiGene), and others, are developing novel EGFR inhibitors that can be available in the EGFR inhibitors market in the coming years. Some of the key EGFR inhibitors in clinical trials include Zipalertinib (CLN-081), Firmonertinib, Ivonescimab (SMT112), PF-08046054, Patritumab Deruxtecan, Sacituzumab Tirumotecan, (MK-2870), SYS6010, JMT101, Izalontamab Brengitecan (BMS-986507), Telisotuzumab Adizutecan (Temab-A/ABB-400), LP-300, WSD0922-FU, Sutetinib, Quaratusugene ozeplasmid (REQORSA), JIN-A02, Silevertinib, (BDTX-1535), BH-30643, STX-241/PFL-241, STX-721/PFL-271, A2B395, BNT326 (YL 202), DF9001, Pamvatamig (MCLA-129), TAS3351, DB-1310, Enozertinib (ORIC-114 ), BG-60366, and others. In 2036, among all the therapies for EGFR NSCLC, the highest revenue is estimated to be generated by amivantamab (RYBREVANT) ± lazertinib (LAZCLUZE), followed by osimertinib (TAGRISSO), in the US. Discover which EGFR drugs will lose patent exclusivity @ Key Factors Driving the EGFR Inhibitors Market Rising Prevalence of Cancer: Increasing incidence of non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and head & neck cancers is driving demand for targeted therapies. The growing global cancer burden is expanding the patient pool eligible for EGFR-targeted treatment. Advancements in Precision Medicine: Greater adoption of biomarker-based treatment approaches is supporting the use of EGFR inhibitors in mutation-specific patient populations. Routine molecular testing for EGFR mutations has improved patient identification and treatment selection. Growth in Combination Therapy Approaches: Increasing use of EGFR inhibitors in combination with immunotherapies, chemotherapy, and anti-angiogenic agents is improving clinical outcomes. Combination regimens are helping overcome resistance mechanisms and extending treatment duration. Strong Pipeline and Ongoing Clinical Research: The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSPC Pharmaceutical), JMT101 (Shanghai JMT-Bio), Izalontamab Brengitecan (BMS-986507) (Bristol-Myers Squibb), Telisotuzumab Adizutecan (Temab-A/ABB-400) (AbbVie), LP-300 (Lantern Pharma), WSD0922-FU (Wayshine Biopharm), Sutetinib (Teligene US), Quaratusugene ozeplasmid (REQORSA) (Genprex), JIN-A02 J (Ints Bio), Silevertinib (BDTX-1535) (Black Diamond Therapeutics), BH-30643 (BlossomHill Therapeutics), STX-241/PFL-241 (Scorpion Therapeutics/Pierre Fabre), STX-721/PFL-271 (Antares Therapeutics), A2B395 (A2 Biotherapeutics), BNT326 (YL 202) (BioNTech), DF9001 (Dragonfly Therapeutics), Pamvatamig (MCLA-129) (Merus), TAS3351 (Taiho Oncology), DB-1310 (DualityBio), Enozertinib (ORIC-114) (ORIC Pharmaceuticals), BG-60366 (BeOne Medicines), and others. The expected launch of these therapies shall further create a positive impact on the market. Aparna Thakur, an oncology expert at DelveInsight, said that Exon 20 insertion has emerged as a key competitive arena, with the approvals of RYBREVANT and ZEGFROVY creating a new market segment, while several late-stage candidates, including furmonertinib and zipalertinib, are further heightening the competitive landscape. EGFR Inhibitors Market Analysis Treatment approaches for EGFR-mutated NSCLC have advanced significantly over the last two decades with the development of targeted EGFR tyrosine kinase inhibitors (TKIs). First-generation agents such as erlotinib and gefitinib, followed by second-generation therapies including afatinib and dacomitinib, and later the third-generation TKI osimertinib, have consistently demonstrated improved clinical outcomes over conventional chemotherapy in terms of response rates and survival. Osimertinib additionally addresses the T790M resistance mutation, although acquired resistance continues to limit long-term efficacy, leaving post-TKI treatment strategies an ongoing clinical challenge. Currently, osimertinib continues to serve as the global standard of care for EGFR-mutant NSCLC, supported by robust progression-free survival (PFS) and overall survival (OS) benefits along with extensive regulatory approvals across multiple disease stages. At the same time, amivantamab is emerging as a strong competitor, broadening its role beyond EGFR exon 20 insertion mutations through combination approaches involving lazertinib and chemotherapy. Competitive intensity within the market is increasing with the arrival of newer therapies such as datopotamab deruxtecan, sunvozertinib, and aumolertinib. Real-world evidence from the 7MM highlights the continued dominance of EGFR TKIs in treatment practice, particularly the widespread frontline adoption of osimertinib, while chemotherapy and immunotherapy continue to play roles in later-line settings and in patients harboring uncommon mutations such as exon 20 insertions. Cetuximab (ERBITUX), an anti-EGFR IgG1 monoclonal antibody, is projected to retain a steady but mature market presence in metastatic colorectal cancer (mCRC) and head and neck cancers. Its position is reinforced by extensive clinical experience, a well-established efficacy profile, and approvals from major regulatory agencies, including the U.S. FDA, EMA, and PMDA. In mCRC, cetuximab remains especially relevant in biomarker-driven settings, particularly among patients with EGFR-expressing and RAS wild-type tumors. Its utility is further strengthened through combination regimens with targeted agents such as encorafenib for BRAF V600E-mutated disease and adagrasib for KRAS G12C-mutated tumors. In head and neck cancers, cetuximab continues to see stable use in combination therapies and among patients who are unsuitable for certain systemic or immunotherapy-based approaches. Nevertheless, despite sustained clinical utilization across key markets, market expansion is expected to be moderate owing to product maturity, biosimilar competition, and the growing adoption of newer targeted therapies and immuno-oncology treatments. EGFR exon 20 insertion-positive NSCLC remains particularly challenging to manage with conventional TKIs. Following the withdrawal of mobocertinib, amivantamab became the primary approved therapeutic option in this segment. However, the approval of sunvozertinib in 2025 has intensified competition, while additional TKIs such as furmonertinib and zipalertinib continue to advance through clinical development. The emergence of ADCs such as PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSPC Pharmaceutical), Izalontamab Brengitecan (BMS-986507) (Bristol-Myers Squibb), Telisotuzumab Adizutecan (Temab-A/ABB-400) (AbbVie), and others, and next-generation targeted therapies is further reshaping and intensifying the competitive dynamics within the EGFR NSCLC treatment landscape. Learn more about the fastest growing EGFR inhibitor market @ EGFR Inhibitors Analysis EGFR Inhibitors Competitive Landscape Some of the emerging EGFR inhibitors in the clinical trial landscape include Zipalertinib (CLN-081) (Cullinan Oncology/Taiho Pharma), Firmonertinib (ArriVent BioPharma), Ivonescimab (SMT112) (Akeso Biopharma/Summit Therapeutics), PF-08046054 (Pfizer), Patritumab Deruxtecan (Daiichi Sankyo/AstraZeneca), Sacituzumab Tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSPC Pharmaceutical), JMT101 (Shanghai JMT-Bio), Izalontamab Brengitecan (BMS-986507) (Bristol-Myers Squibb), Telisotuzumab Adizutecan (Temab-A/ABB-400) (AbbVie), LP-300 (Lantern Pharma), WSD0922-FU (Wayshine Biopharm), Sutetinib (Teligene US), Quaratusugene ozeplasmid (REQORSA) (Genprex), JIN-A02 J (Ints Bio), Silevertinib (BDTX-1535) (Black Diamond Therapeutics), BH-30643 (BlossomHill Therapeutics), STX-241/PFL-241 (Scorpion Therapeutics/Pierre Fabre), STX-721/PFL-271 (Antares Therapeutics), A2B395 (A2 Biotherapeutics), BNT326 (YL 202) (BioNTech), DF9001 (Dragonfly Therapeutics), Pamvatamig (MCLA-129) (Merus), TAS3351 (Taiho Oncology), DB-1310 (DualityBio), Enozertinib (ORIC-114) (ORIC Pharmaceuticals), BG-60366 (BeOne Medicines), and others. Akeso's ivonescimab (AK112, SMT112) is a novel PD-1/VEGF bispecific antibody and the first agent of its kind to advance into Phase III clinical testing. Developed using the company's proprietary Tetrabody platform, the therapy is designed to simultaneously inhibit PD-1 interactions with PD-L1 and PD-L2 while also blocking VEGF from binding to its receptors. Simultaneous inhibition of the PD-1 and VEGF pathways has demonstrated notable clinical benefits across several cancers, including NSCLC, renal cell carcinoma, and hepatocellular carcinoma. By integrating both mechanisms into a single therapeutic molecule, ivonescimab may enable broader pathway suppression and potentially provide superior antitumor efficacy compared with conventional combination approaches. The US FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab, supported by findings from the Phase III HARMONi trial, and has set a PDUFA action date of November 14, 2026. ArriVent BioPharma and Shanghai Allist Pharmaceuticals' Firmonertinib, previously referred to as furmonertinib, is an orally administered, mutation-selective EGFR inhibitor recognized for its strong CNS penetration and activity against a broad spectrum of EGFR mutations, including uncommon variants such as PACC and Exon 20 insertion mutations. The therapy is currently being investigated in the global Phase III FURVENT trial (NCT05607550) as a first-line option for NSCLC patients with EGFR Exon 20 insertion mutations. At the same time, the global Phase Ib FURTHER study (NCT05364043) is evaluating its efficacy in patients with EGFR PACC mutations. In addition, firmonertinib is being explored in combination regimens for advanced or metastatic NSCLC with classical EGFR mutations through a collaboration with InnoCare Pharma. Cullinan Therapeutics and Taiho Pharma's Zipalertinib is a next-generation, irreversible oral EGFR inhibitor specifically developed to selectively target tumors carrying EGFR exon 20 insertion mutations while sparing wild-type EGFR activity. Preclinical findings indicate that this mutant-selective design may help mitigate the toxicities commonly associated with inhibition of wild-type EGFR. The molecule's distinct chemical structure is also intended to minimize HER2 inhibition, thereby improving selectivity further. Due to its targeted mechanism and encouraging clinical data, zipalertinib is gaining attention as a potential treatment option for EGFR exon 20 insertion-mutated NSCLC. Taiho Pharmaceutical and Cullinan Therapeutics recently announced that the FDA has accepted the NDA for zipalertinib for patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease progressed after platinum-based chemotherapy, with or without prior amivantamab treatment. The application has been assigned a PDUFA target date of February 27, 2027. The anticipated launch of these emerging therapies are poised to transform the EGFR inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the EGFR inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about companies developing EGFR inhibitors, visit @ EGFR Inhibitors Treatment Recent Developments in the EGFR Inhibitors Market In April 2026, Taiho Oncology, Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. announced that the FDA had accepted the NDA for zipalertinib to treat patients with locally advanced or mNSCLC harboring EGFR ex20ins mutations whose disease has progressed following platinum-based chemotherapy, with or without prior amivantamab treatment. The FDA has assigned a PDUFA target action date of February 27, 2027. In February 2026, J INTS BIO announced that research findings on JIN-A02 had been published in Clinical Cancer Research, a leading oncology journal published by the American Association for Cancer Research (AACR). In February 2026, the FDA approved once-monthly RYBREVANT FASPRO + LAZCLUZE for 1L EGFR-mutated advanced NSCLC. In January 2026, the US FDA accepted for filing Summit's Biologics License Application (BLA) seeking approval for the HARMONi trial (Phase III). The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026. In December 2025, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for AUMSEQA in adult NSCLC, covering first-line EGFR-mutant disease and EGFR T790 M-mediated acquired resistance. What are EGFR Inhibitors? EGFR inhibitors are a class of targeted therapies designed to block the activity of the epidermal growth factor receptor (EGFR), a protein that plays a critical role in regulating cell growth, survival, and proliferation. In many cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, head and neck cancer, and glioblastoma, EGFR is either overexpressed or mutated, leading to uncontrolled tumor growth. EGFR inhibitors work by interfering with the signaling pathways activated by this receptor, thereby slowing or stopping cancer cell proliferation. These therapies are broadly categorized into tyrosine kinase inhibitors (TKIs), which target the intracellular kinase domain of EGFR, and monoclonal antibodies, which bind to the extracellular portion of the receptor. Over the past decade, EGFR inhibitors have transformed the treatment landscape of several solid tumors by enabling more personalized and biomarker-driven therapeutic approaches. EGFR Inhibitors Epidemiology Segmentation The EGFR inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets. The EGFR inhibitors target patient pool is segmented into: Total Incident Cases of EGFR Inhibitor Total Incident cases of EGFR by Indication Scope of the EGFR Inhibitors Market Report EGFR Inhibitors Patient Population Forecast EGFR Inhibitors Therapeutics Market Size EGFR Inhibitors Pipeline Analysis EGFR Inhibitors Market Size and Trends EGFR Inhibitors Market Opportunity EGFR Inhibitors Market Unmet Needs KOL's Views on EGFR Inhibitors EGFR Inhibitors Market Access and Reimbursement Discover the best emerging EGFR inhibitors in pipeline @ EGFR Inhibitors Clinical Trials Table of Contents Related Reports EGFR NSCLC Market EGFR NSCLC Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key EGFR NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hansoh Pharmaceutical, Johnson & Johnson Innovative Medicine, Pfizer, Cullinan Oncology, Taiho Pharmaceutical, ArriVent Biopharma, Black Diamond Therapeutics, Daiichi Sankyo, Akeso Biopharma, Summit Therapeutics, and others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene , Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK and others. Colorectal Cancer Market Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CRC companies, including Shanghai Henlius Biotech, Agenus, Tizona Therapeutics, Surgimab, Novartis, Bexion Pharmaceuticals, Syndax Pharmaceuticals, Exelixis, AbbVie, Tyligand Pharmaceuticals, Bristol Myers Squibb, Eisai, Bold Therapeutics, Takeda, Merck Sharp & Dohme, and others Head and Neck Cancer Market Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key HNC companies, including CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 SOURCE DelveInsight Business Research, LLP 21% more press release views with Request a Demo